Platelet aggregability is modulated by eNOS locus in non-type 2 diabetic patients with acute coronary syndrome

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 21, Issue 1, 2011, Pages 11-17

  Fatini, C ^a,b   Sticchi, E ^a,b   Bolli, P ^c   Marcucci, R ^a,b   Giusti, B ^a,b   Paniccia, R ^a,b   Gori, A M ^a,b   Gensini, G F ^c   Abbate, R ^a,b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Acute coronary syndrome; Diabetes; ENOS locus; Platelet aggregability

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; ARACHIDONIC ACID; COLLAGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALLELE; ARTICLE; BLOOD; COHORT ANALYSIS; FEMALE; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOLOGY; PHYSIOLOGY; STATISTICAL MODEL; THROMBOCYTE AGGREGATION; VASCULAR ENDOTHELIUM;

ACUTE CORONARY SYNDROME; ADENOSINE DIPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARACHIDONIC ACID; COHORT STUDIES; COLLAGEN; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; FEMALE; GENOTYPE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC;

EID: 78751611887     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.07.001     Document Type: Article

References (33)

1. Freedman J.E., Ting B., Hankin B., Loscalzo J., Keaney J.F., Vita J.A. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998, 98:1481-1486.
2. Vinik A.I., Erbas T., Park T.S., Nolan R., Pittenger G.L. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001, 24:1476-1485.
3. Worthley M.I., Holmes A.S., Willoughby S.R., Kucia A.M., Heresztyn T., Stewart S., et al. The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol 2007, 49:304-310.
4. Freedman J.E., Loscalzo J., Barnard M.R., Alpert C., Keaney J.F., Michelson A.D. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1995, 100:350-356.
5. Mehta J.L., Chen L.Y., Kone B.C., Mehta P., Turner P. Identification of constitutive and inducible forms of nitric oxide synthase in human platelets. J Lab Clin Med 1995, 125:370-377.
6. Freedman J.E., Sauter R., Battinelli E.M., Ault K., Knowles C., Huang P.L., et al. Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene. Circ Res 1999, 84:1416-1421.
7. Gambaryan S., Kobsar A., Hartmann S., Birschmann I., Kuhlencordt P.J., Müller-Esterl W., et al. NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost 2008, 6:1376-1384.
8. Veldman B.A., Spiering W., Doevendans P.A., Vervoort G., Kroon A.A., de Leeuw P.W., et al. The Glu298Asp polymorphisms of the NOS3 gene as a determinant of the baseline production of nitric oxide. J Hypertens 2002, 20:2023-2027.
9. Nakayama M., Yasue H., Yoshimura M., Shimasaki Y., Kugiyama K., Ogawa H., et al. T-786C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999, 99:2864-2870.
10. Tsukada T., Yokoyama K., Arai T., Takemoto F., Hara S., Yamada A., et al. Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans. Biochem Biophys Res Commun 1998, 245:190-193.
11. Dosenko V.E., Zagoriy V.Y., Haytovich N.V., Gordok O.A., Moibenko A.A. Allelic polymorphism of endothelial NO-synthase gene and its functional manifestations. Acta Biochim Pol 2006, 53:299-302.
12. Fatini C., Sofi F., Sticchi E., Gensini F., Gori A.M., Fedi S., et al. Influence of endothelial nitric oxide synthase gene polymorphisms (G894T, 4a4b, T-786C) and hyperhomocysteinemia on the predisposition to acute coronary syndromes. Am Heart J 2004, 147:516-521.
13. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312-2317.
14. Giusti B., Gori A.M., Marcucci R., Saracini C., Sestini I., Paniccia R., et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007, 17:1057-1064.
15. Marcucci R., Gori A.M., Paniccia R., Giusti B., Valente S., Giglioli C., et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 2009, 119:237-242.
16. Paniccia R., Antonucci E., Gori A.M., Marcucci R., Poli S., Romano E., et al. Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment. Am J Clin Pathol 2007, 128:143-149.
17. Gum P.A., Kottke-Marchant K., Welsh P.A., White J., Topol E.J. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003, 41:961-965.
18. Sticchi E., Lenti M., Giusti B., Sestini I., Abbate R., Fatini C. LPA +93C>T and +121G>A polymorphisms detection by electronic microchip technology. Mol Genet Metab 2007, 91:79-84.
19. Marcucci R., Gori A.M., Paniccia R., Giglioli C., Buonamici P., Antoniucci D., et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis 2007, 195:e217-e223.
20. Bolli P., Sticchi E., Abbate R., Fatini C. A novel allele of eNOS gene in the Italian population: the actual essence of intron 4 polymorphism. Nitric Oxide 2007, 16:392-394.
21. Becker T., Cichon S., Jönson E., Knapp M. Multiple testing in the context of haplotype analysis revisited: application to case-control data. Ann Hum Genet 2005, 69:747-756.
22. Madajka M., Korda M., White J., Malinski T. Effect of aspirin on constitutive nitric oxide synthase and the biovailability of NO. Thromb Res 2003, 110:317-321.
23. Ezzidi I., Mtiraoui N., Mohamed M.B., Mahjoub T., Kacem M., Almawi W.Y. Association of endothelial nitric oxide synthase Glu298Asp, 4b/a, and -786T>C gene variants with diabetic nephropathy. J Diabetes Complications 2008, 22:331-338.
24. de Syllos R.W., Sandrim V.C., Lisboa H.R., Tres G.S., Tanus-Santos J.E. Endothelial nitric oxide synthase genotype and haplotype are not associated with diabetic retinopathy in diabetes type 2 patients. Nitric Oxide 2006, 15:417-422.
25. Radomski M.W., Palmer R.M., Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990, 87:5193-5197.
26. Matsuoka I., Nakahata N., Nakanishi H. Inhibitory effect of 8-bromo cyclic GMP on an extracellular Ca2+-dependent arachidonic acid liberation in collagen-stimulated rabbit platelets. Biochem Pharmacol 1989, 38:1841-1847.
27. Wang G.R., Zhu Y., Halushka P.V., Lincoln T.M., Mendelsohn M.E. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc Natl Acad Sci U S A 1998, 95:4888-4893.
28. Li Z., Xi X., Gu M., Feil R., Ye R.D., Eigenthaler M., et al. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell 2003, 112:77-86.
29. Morrell C.N., Matsushita K., Chiles K., Scharpf R.B., Yamakuchi M., Mason R.J., et al. Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci U S A 2005, 102:3782-3787.
30. Zhang M.X., Zhang C., Shen Y.H., Wang J., Li X.N., Chen L., et al. Effect of 27nt small RNA on endothelial nitric-oxide synthase expression. Mol Biol Cell 2008, 19:3997-4005.
31. Vignini A., Nanetti L., Moroni C., Testa R., Sirolla C., Marra M., et al. Platelet nitric oxide production and IR: Relation with obesity and hypertriglyceridemia. Nutr Metab Cardiovasc Dis 2008, 18:553-558.
32. Ferretti G., Rabini R.A., Bacchetti T., Vignini A., Salvolini E., Ravaglia F., et al. Glycated low density lipoproteins modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 2002, 87:2180-2184.
33. Oak J.H., Cai H. Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007, 56:118-126.